Lyra Therapeutics, Inc.

NasdaqGM:LYRA Stok Raporu

Piyasa değeri: US$12.4m

Lyra Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Maria Palasis

İcra Kurulu Başkanı

US$1.8m

Toplam tazminat

CEO maaş yüzdesi32.7%
CEO görev süresi9.8yrs
CEO sahipliğin/a
Yönetim ortalama görev süresi2.3yrs
Yönetim Kurulu ortalama görev süresi4.1yrs

Son yönetim güncellemeleri

Recent updates

Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

Jan 25
Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Sep 10
We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 12
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Lyra Therapeutics appoints Nieman as Chief Medical Officer

Jul 05

Lyra Therapeutics: Progress In The Clinic

May 18

A First Look At Lyra Therapeutics

Apr 21

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 30
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

Dec 14
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

Aug 28
We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

May 04
We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Mar 05
How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Jan 11
Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Lyra Therapeutics down 19% underwhelming data from lead program

Dec 07

Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis

Nov 24

CEO Tazminat Analizi

Maria Palasis'un ücretlendirmesi Lyra Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$98m

Jun 30 2024n/an/a

-US$101m

Mar 31 2024n/an/a

-US$69m

Dec 31 2023US$2mUS$583k

-US$63m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$61m

Mar 31 2023n/an/a

-US$60m

Dec 31 2022US$2mUS$583k

-US$55m

Sep 30 2022n/an/a

-US$55m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$48m

Dec 31 2021US$2mUS$552k

-US$44m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$32m

Mar 31 2021n/an/a

-US$26m

Dec 31 2020US$4mUS$471k

-US$22m

Sep 30 2020n/an/a

-US$20m

Jun 30 2020n/an/a

-US$18m

Mar 31 2020n/an/a

-US$17m

Dec 31 2019US$843kUS$388k

-US$17m

Tazminat ve Piyasa: Maria 'nin toplam tazminatı ($USD 1.79M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 649.07K ).

Tazminat ve Kazançlar: Maria şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Maria Palasis (59 yo)

9.8yrs

Görev süresi

US$1,785,375

Tazminat

Dr. Maria Palasis, Ph D, serves as Director at PanTher Therapeutics, Inc. since June 2021. Dr. Palasis has been Chief Executive Officer, President and Director of Lyra Therapeutics, Inc. since January 2015...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Harlan Waksal
Executive Chairman2.8yrsUS$625.06k0.40%
$ 49.5k
Maria Palasis
CEO, President & Director9.8yrsUS$1.79mVeri yok
Carmichael Roberts
Co-Founderno dataVeri yokVeri yok
Jason Cavalier
CFO, Treasurer & Secretary3.2yrsUS$1.07mVeri yok
Ray Knox
Vice President of Operationsno dataVeri yokVeri yok
Ronan O'Brien
Chief Legal Officer1.1yrsVeri yokVeri yok
Vineeta Belanger
Senior Vice President of Clinical Affairsno dataVeri yokVeri yok
Robert Richard
Senior Vice President of Technical Operations1.8yrsUS$666.79kVeri yok
Robert Kern
Chief Clinical Advisor3.8yrsVeri yokVeri yok
Gloria Cosgrove
Senior Vice President of Quality1.8yrsVeri yokVeri yok
Allison Nance
Senior Vice President of Regulatory Affairs1.8yrsVeri yokVeri yok
Elazer Edelman
VP of Finance & Riskno dataVeri yokVeri yok

2.3yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: LYRA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.3 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Harlan Waksal
Executive Chairman2.8yrsUS$625.06k0.40%
$ 49.5k
Maria Palasis
CEO, President & Director9.8yrsUS$1.79mVeri yok
James Tobin
Lead Independent Director2.7yrsUS$152.31k0%
$ 0
W. Smith
Independent Director5yrsUS$123.81k0%
$ 0
George Whitesides
Member of Scientific Advisory Board4.1yrsUS$333.93kVeri yok
C. Merrifield
Independent Director5.2yrsUS$113.06k0.017%
$ 2.1k
Robert Langer
Member of Scientific Advisory Board4.1yrsUS$19.36kVeri yok
Michael Dake
Member of Medical Advisory Boardno dataVeri yokVeri yok
William Gray
Member of Medical Advisory Boardno dataVeri yokVeri yok
Mahmood Razavi
Member of Medical Advisory Boardno dataVeri yokVeri yok
Gary Ansel
Member of Medical Advisory Boardno dataVeri yokVeri yok
I. Baumgartner
Member of Medical Advisory Boardno dataVeri yokVeri yok

4.1yrs

Ortalama Görev Süresi

73yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LYRA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.1 yıldır).